At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 60 enrolled
Drug / intervention
Atorvastatin calcium (Lipitor)drug
Likely dose
Atorvastatin calcium (Lipitor) 40 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase II Study Evaluating the Safety and Efficacy of Atorvastatin for the Prophylaxis of Acute Graft-versus-host Disease in Patients Undergoing Matched Sibling Hematopoietic Stem Cell Transplantation
In Brief
A Phase 2 clinical trial evaluating Atorvastatin calcium (Lipitor) for Graft vs Host Disease. Completed, enrolled 60 participants across 1 site.
Detailed Summary
Atorvastatin for prevention of acute GVHD
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsGraft vs Host Disease
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
Enrollment StartJul 2010
First PostedAug 2010
Primary CompletionDec 2014
TodayJul 2026
First PostedAug 4, 2010
Enrollment StartJul 1, 2010
Primary CompletionDec 1, 2014
TodayJul 2, 2026
Enrollment to primary: 4.4 yearsPosted 15.9 years ago
Interventions
Atorvastatin calcium (Lipitor)drug
40 mg PO daily